NASDAQ: MAZEMaze Therapeutics Inc Stock
$13.40-0.15 (-1.11%)
Updated Jun 13, 2025
MAZE Price
$13.40
Fair Value Price
$32.23
Market Cap
$586.88M
52 Week Low
$6.71
52 Week High
$17.00
P/E
N/A
P/B
2.01x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
N/A
Earnings
N/A
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.14
Operating Cash Flow
N/A
Beta
0.77
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
MAZE Overview
Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of renal, cardiovascular, related metabolic diseases, and obesity in the United States. Its lead programs includes MZE829, an oral small molecule inhibitor of apolipoprotein L1, which is in phase II clinical trial for the treatment of patients with APOL1 kidney disease; and MZE782, an oral small molecule inhibitor of the solute transporter SLC6A19, which is in phase I clinical trial for the treatment of chronic kidney disease. Maze Therapeutics, Inc. was formerly known as Modulus Therapeutics, Inc. and changed its name to Maze Therapeutics, Inc. in September 2018. The company was incorporated in 2017 and is based in South San Francisco, California.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine MAZE's potential to beat the market
DSell
- Stocks with a Zen Rating of Sell (D) had an average loss of -4.50% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
MAZE
Ranked#312 of 464
Ranked#312 of 464
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $8.18 | A | |
| $41.59 | A | |
| $23.53 | A |
Be the first to know about important MAZE news, forecast changes, insider trades & much more!
MAZE News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how MAZE scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
MAZE ($13.40) is undervalued by 58.43% relative to our estimate of its Fair Value price of $32.23 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
MAZE ($13.40) is significantly undervalued by 58.43% relative to our estimate of its Fair Value price of $32.23 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
MAZE is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
There are 30 more MAZE due diligence checks available for Premium users.
Valuation
MAZE fair value
Fair Value of MAZE stock based on Discounted Cash Flow (DCF)
Price
$13.40
Fair Value
$32.23
Undervalued by
58.43%
MAZE ($13.40) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
MAZE ($13.40) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
MAZE price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
2.01x
Industry
4.66x
MAZE is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
MAZE's financial health
Profit margin
Revenue
$0.0
Net Income
-$32.8M
Profit Margin
0%
Assets to liabilities
Assets
$332.8M
Liabilities
$40.8M
Debt to equity
0.14
MAZE's short-term assets ($299.71M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
MAZE's short-term assets ($299.71M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
MAZE's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$29.5M
Investing
-$299.0k
Financing
$127.4M
MAZE vs Biotech Stocks
Maze Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.